Clinical Trials Logo

Rhinitis clinical trials

View clinical trials related to Rhinitis.

Filter by:

NCT ID: NCT05819203 Completed - Common Cold Clinical Trials

BАbykids Spray In Common Cold

BASICC
Start date: February 13, 2023
Phase: N/A
Study type: Interventional

The purpose of this post market clinical investigation is to demonstrate that Healsea® Babykids alleviates symptoms of the acute rhinitis phase with better efficacy than isotonic saline solution used as Placebo in children above 2 years.

NCT ID: NCT05810233 Recruiting - Allergy Clinical Trials

Effect of Vitamin C on Allergy Skin Test

Start date: July 15, 2023
Phase: N/A
Study type: Interventional

This study will assess the effect of taking vitamin C on allergy skin test.

NCT ID: NCT05779046 Completed - Allergic Rhinitis Clinical Trials

Acute Effect of High Intensity Interval Exercise in Patients With Allergic Rhinitis

Start date: September 10, 2022
Phase: N/A
Study type: Interventional

The purpose of this study was to determine the acute effect of high intensity interval exercise on respiratory function and rhinitis symptoms in allergic rhinitis patients.

NCT ID: NCT05755477 Recruiting - Clinical trials for Eosinophilic Esophagitis

Survey About the Relationship Beetween Allergic Rhinitis and Seasonal EOE Exacerbations

Start date: January 3, 2021
Phase:
Study type: Observational

Eosinophilic esophagitis (EoE) is a chronic inflammatory esophagus disease that is presented in patients with a history of recurrent dysphagia. EoE is closely related to other pathologies with an immuno-allergic etiopathogenesis such as atopic dermatitis (AD), IgE-mediated food allergy, allergic rhinitis and bronchial asthma. While the importance of the correlation between diet and food allergy has been largely demonstrated, less is known about the exact role of sensitization to aerollergens in the progression and recrudescence of symptoms. In support of this correlation there is evidence of a seasonal trend in the new diagnoses of EoE, of the possibility of the de-novo onset of the pathology following massive exposure to a specific aeroallergen and the demonstration that the degree of esophageal eosinophilia varies according to the climatic zone and the season of the year. The detailed knowledge of this correlation could clarify some aspects of the etiopathogenesis and natural history of EoE, improve and personalize the clinical-diagnostic management of affected patients and provide new therapeutic targets. Our aim is evaluating the possible existence of a correlation between the recrudescence of dysphagia symptoms and a specific month of the year and/or specific season.

NCT ID: NCT05753241 Completed - COVID-19 Clinical Trials

the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19

Start date: November 10, 2022
Phase:
Study type: Observational [Patient Registry]

At present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection to evaluate the symptoms of AR patients during infection and to provide preventive treatment in advance. So this experiment was designed.

NCT ID: NCT05724290 Enrolling by invitation - Rhinitis, Allergic Clinical Trials

Mechanism of EGR2 in Allergic Rhinitis

Start date: January 30, 2023
Phase: Phase 1
Study type: Interventional

EGR2 may be a target for the treatment of nasal polyps.

NCT ID: NCT05720455 Not yet recruiting - Rhinitis Allergic Clinical Trials

Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above

FAST
Start date: July 21, 2024
Phase: Phase 4
Study type: Interventional

This is a single group, Phase IV clinical trial to assess the safety and effectiveness of Allegra® D. This study will be conducted in participants with allergic rhinitis who are 12 years of age and above. The individual study duration for each participant would be approximately 16 days (maximum of 13 days intervention + a 3-day post intervention observation). There would be 4 study visits in which the last visit can be done either telephonically or on site. Safety events would be captured for the entire study duration. In addition, the effectiveness of the study drug would be assessed using Nasal symptom score (NSS) and Total symptom score (TSS).

NCT ID: NCT05709977 Completed - Allergic Rhinitis Clinical Trials

Acupuncture for Nasal Congestion in Allergic Rhinitis

ANCAR
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

Allergic rhinitis (AR) is a disorder that affects more than 500 million people worldwide. Nasal congestion is one of the most general and bothersome symptoms in rhinitis, which affects the quality of life (QOL). Current medications are undesirable due to their side-effects. Acupuncture for AR in general can be considered as safe and can be seen as a potential therapeutic intervention for nasal congestion. Evidence supported that acupuncture is clinically used for signs and symptoms of nose disorders, such as nasal congestion, with effectiveness, but whether acupuncture has immediate, post-treatment and long-term effects on nasal congestion in AR is not verified by strictly designed clinical study. The ANCAR trial uses a standard treatment protocol with a fixed set of acupuncture points - to be as scientific as possible from Western medical viewpoint - to open the nose and affect underlying energetic imbalance and immunity at the same time, to maintain its nose opening effect. This novel acupuncture treatment protocol can be seen as a solid and profound approach from which every AR patient may benefit.

NCT ID: NCT05708157 Recruiting - Allergic Rhinitis Clinical Trials

Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

INCS/INAH
Start date: January 17, 2023
Phase:
Study type: Observational

Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

NCT ID: NCT05707611 Completed - Allergic Rhinitis Clinical Trials

Acute Effects of Various Aerobic Exercise in Allergic Rhinitis.

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

This study was to investigate the comparison among acute effects of various aerobic exercise on symptoms in allergic rhinitis patients.